Percutaneous cryoablation for advanced and refractory extra-abdominal desmoid tumors
Authors:
- Pierre AulogePAPierre Auloge
- Julien GarnonJGJulien Garnon
- Joey Marie RobinsonJRJoey Marie Robinson
- Marie-Aude ThenintMTMarie-Aude Thenint
- Guillaume KochGKGuillaume Koch
- Jean CaudrelierJCJean Caudrelier
- Julia WeissJWJulia Weiss
- Roberto Luigi CazzatoRCRoberto Luigi Cazzato
- Jean Emmanuel KurtzJKJean Emmanuel Kurtz
- Afshin GangiAGAfshin Gangi
- 11 March 2021
- journal article
- research article
- Published by Springer Nature in International Journal of Clinical Oncology
- Vol. 26 (6) , 1147-1158
Abstract
Purpose To assess efficacy and safety of percutaneous cryoablation (CA) for advanced and refractory extra-abdominal desmoid tumors. Materials and methods This retrospective study reviewed 30 consecutive patients with symptomatic desmoid tumors evolving after “wait and watch” periods, and despite medical treatment, treated by CA between 2007 and 2019. Progression free survival (PFS), objective response rate, pain reduction (decreased of visual analogic scale pain (VAS)\(\ge\) 3 or disappearance of pain), total volume lesion (TVL) and complications were documented. Kaplan Meier method was used to outline PFS. Paired sample t test was used to compare volume of tumors before treatment and at 1 and 3 year. Results With a median follow-up of 18.5 months (range 6–93 months, interquartile range (IQR): 12–55), the PFS was 85.1% at 1 year and 77.3% at 3 years. Objective response was obtained for 80% of patients with a complete response for 43% patients. Pain reduction was obtained for 96.7% (95% confidence interval (95% CI): 90.3, 100) of patients. Median volume of desmoid tumor before treatment was 124.1cm3 (range 2–1727cm3, IQR: 54–338cm3). Median change of TLV after ablation was 66.6% (95% CI: 37.2, 72.3; p = 0.002) at 1 year and 76.4% (95% CI: 59.1, 89.8; p = 0.002) at 3 year. Adverse events rate was 36.6%, the most common was edema and temporary increase of pain in the days following CA. Four patients experienced a major complication (13.3%): 2 skin necrosis, 1 infection and 1 brachial plexopathy. Conclusion CA is an effective treatment for advanced and refractory extra-abdominal desmoid tumor, that induces durable responses.
Keywords
This publication has 31 references indexed in Scilit:
- Percutaneous Thermal Ablation: How to Protect the Surrounding OrgansTechniques in Vascular and Interventional Radiology, 2011
- Current Perspectives on Desmoid Tumors: The Mayo Clinic ApproachCancers, 2011
- A nation‐wide study comparing sporadic and familial adenomatous polyposis‐related desmoid‐type fibromatosesInternational Journal of Cancer, 2010
- Quality Improvement Guidelines for Bone Tumour ManagementCardioVascular and Interventional Radiology, 2010
- Isothermal volume contours generated in a freezing gel by embedded cryo-needles with applications to cryo-surgeryCryobiology, 2007
- Risks and Benefits of Patient Positioning During Neurosurgical CareAnesthesiology Clinics, 2007
- Desmoid Tumors – a Characterization of Patients Seen at Mayo Clinic 1976–1999Familial Cancer, 2006
- Desmoid tumoursEuropean Journal of Surgical Oncology, 2001
- Two Freezing Cycles Ensure Interface Sterilization by Cryosurgery during Bone Tumor ResectionCryobiology, 2001
- Genotype and phenotype factors as determinants of desmoid tumors in patients with familial adenomatous polyposisInternational Journal of Cancer, 2001